Find Drugs for Infections and Infectious Diseases in Phase I Clinical Development in CHINA

Lead Product(s): INO-4800

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Inovio Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 30, 2020

Details:

The goal of this collaboration is to leverage Advaccine's expertise to run a Phase 1 trial in China in parallel with Inovio's clinical development efforts in the U.S.

Lead Product(s): ASC22

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

ASC22 is a first-in-class, subcutaneously administered PD-L1 antibody approved for such clinical trials in HBV patients on a global basis.